A careful appraisal of the specific context concurring in each particular disease, considering the nature of the brain insult (infection, injury, stroke, neurodegeneration, etc.)and its persistence over time, and the impact of the treatment on both central and peripheral myeloid cells, should help to address the advisability of exploring the therapeutic potential of a moderate blockade of CSF1R signaling by using low doses of CSF1R inhibitors. This evidence concerns the gene CSF1R and Stroke.